Meet TIEFENBACHER GROUP at CPhI in Frankfurt from 1-3 Nov and discover our latest ideas to make pharmaceuticals more affordable, more available, and better than before!

We are very excited to meet our valued customers and partners once again on CPhI 2022, the world´s leading pharma industry event! 

Explore our new booth representing Tiefenbacher Group as a global health pioneer and discover our latest product portfolio and innovations in the field of raw materials, finished dosage forms, and medical devices! Get in touch with our experts to discuss new business opportunities and ideas for improving the life of millions of patients worldwide! 

CPhI 2022 will take place on November 1-3 at Messe Frankfurt, Germany. We’ll be happy to meet you at our stand 80B70 at any time during the event. The arrangement of prescheduled meetings is highly appreciated. Please contact our team to request a meeting or send a meeting request to cphi@aet.eu. 

TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on www.tiefenbachergroup.com 


MEET TIEFENBACHER GROUP AT BEPHARMA IN MEXICO CITY FROM OCTOBER 10-12!

Reach out to AET – TIEFENBACHER PHARMACEUTICALS at BePharma, the most important Pharma B2B Event in Latin America from October 10-12! 

Discover our latest product portfolio in Mexico City and find out how we strive to make pharmaceuticals more affordable, more available, and better than before!  

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu 

TIEFENBACHER PHARMACEUTICALS is as a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com 


NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES GENERIC VERSION OF THE DIABETIS MEDICINE VILDAGLIPTIN AND VILDAGLIPTIN/METFORMIN in AFRICA

We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines available and affordable to as many people as possible around the world. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Vildagliptin and the combination product Vildagliptin/Metformin in Africa.

Vildagliptin and Vildagliptin/Metformin are diabetes medicines that are used to control the blood glucose (sugar) in adults with type 2 diabetes. The tablets are marketed in South Africa (Vildagliptin 50 mg) and Namibia (Vildagliptin/Metformin 50/1000 mg) by our marketing partner, a well-known South African based pharmaceutical company. The products have been developed in TIEFENBACHER GROUP´s own laboratories in Hyderabad, India, and will be marketed in Europe and further international countries as soon as the patents of the originator products have expired.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com


Environmentally friendly and health-promoting: TIEFENBACHER GROUP offers bike leasing to employees

From racing bikes to E-bikes: since this year all our employees at our Hamburg headquarters can choose from a broad range of company bikes to lease. A great opportunity for everyone to stay fit and healthy and fully aligned with TIEFENBACHER GROUP´s strategy of doing business sustainable! As with car leasing, the monthly instalment is deducted from the monthly gross salary through salary conversion.

We are very optimistic to reach soon our target that at least 30% of our Hamburg employees will cycle to work instead of taking their car. One step further on our way to less CO2 emissions!  And of course, we have sufficient bicycle parking spaces in our underground garage – including numerous electric charging station for electric vehicles.

For further information about our corporate social responsibility activities and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


GLOBAL MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS EXPANDS THE LAUNCH OF THE ANTICOAGULANT MEDICINE RIVAROXABAN TO CENTRAL AMERICA AND FURTHER INTERNATIONAL MARKETS

We at TIEFEENBACHER PHARMACEUTICALS strongly believe that our high-quality medicines should be available for all patients around the world – irrespective of their origin or nationality. That´s why we are happy to share that we have successfully expanded the launch of the generic version of Rivaroxaban to Central America, the Caribbean and Kazakhstan.

Rivaroxaban is an anticoagulant medication (blood thinner) used to treat and prevent blood clots. The tablets are marketed in the strengths 10 mg, 15 mg, and 20 mg by our cooperation partner, one of the biggest generic pharmaceutical companies in the world. The product has been developed in TIEFENBACHER GROUP´s own laboratories in Hyderabad, India, and has already been launched in certain patent-free European markets before. A launch in further international countries like Thailand, Albania, Serbia, Peru, Chile, and North Macedonia will follow soon. Overall, our country scope covers about 80 countries around the world. With this global market entry, we enable millions of patients worldwide access to a life- improving, high-quality treatment – also in emerging countries where GMP-compliance is not always a standard yet.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is as a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com


NEW MARKET LAUNCH: TIEFENBACHER PHARMACEUTICALS SUCCESSFULLY LAUNCHES FIRST GENERIC VERSION OF THE MULTIPLE SCLEROSIS MEDICINE TERIFLUNOMIDE IN CANADA

We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Teriflunomide for a market entry on day one after patent expiration in Canada.

Teriflunomide is used to improve the life of patients suffering from Multiple Sclerosis – a chronic disease that effects the central nervous system. The 14 mg film coated tablets are developed and produced in TIEFENBACHER GROUPs own site in India and will be marketed in Canada by our partners, two well-known generic pharmaceutical companies. Our product has already been launched in time in Australia before – a launch in further international markets will follow as soon as the patents of the originator product expire. With this early market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu

TIEFENBACHER PHARMACEUTICALS is as a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com


TIEFENBACHER GROUP becomes member of the Pharmaceutical Supply Chain Initiative (PSCI)

We at TIEFENBACHER GROUP are committed to promote sustainable and responsible business along the whole pharmaceutical supply chain. That’s why we are excited to become a member of PSCI – a non-profit business membership organization striving for better social, health, safety, and environmental outcomes in pharmaceutical supply chains. It follows our company´s strategy to make medicines better affordable, better available, and better than before in a sustainable way – better for people and the planet!

PSCI is a group of international pharmaceutical and healthcare companies who share together the vision of responsible supply chains. The organization was founded in 2006 and is legally established in the United States. Today PSCI already counts 63 members. For more information about the organization have a look at: PSCI (pscinitiative.org) .

For further information about our product portfolio and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


TIEFENBACHER GROUP OPENS NEW SITE FOR HIGHLY POTENT DRUGS IN INDIA

TIEFENBACHER GROUP is excited to announce the ceremonious opening of our new highly potent drug laboratory in Hyderabad, India. The completion of the new building is the first step for TIEFENBACHER GROUP to become a leading global developer and manufacturer of highly potent drugs for the treatment of cancer and other diseases. It follows our company´s strategy to make medicines more affordable, more available, and better than before.

The lab is equipped with the latest techniques with full safety protection measurements and will be extended by an additional manufacturing block with special technologies in 2023. The new complex will cover a total of about 4.000 square meters.

TIEFENBACHER PHARMACEUTICALS (FDF business unit of TIEFENBACHER GROUP) has already 25 leading highly potent drugs in its launch pipeline which are planned to be developed and produced in the new facilities in Hyderabad. While the operational start of the lab (including small-scale production) is planned for this year, the commercial production for larger quantities in the new manufacturing block is expected for 2024.

For further information about our product portfolio and innovative health care solutions for a better tomorrow please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From initial idea to market access of high-quality pharmaceuticals around the world: We distribute APIs and develop, manufacture, and register finished dosage forms (FDF) as well as medical devices. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


WORLD HEALTH DAY @ TIEFENBACHER GROUP

Today we celebrate World Health Day. In times of a global pandemic and a cruel war in Europe, it is more important than ever that we all work together to create a healthier tomorrow. Since 1963 we at TIEFENBACHER GROUP are pioneering healthcare to improve patients´ lives around the world. Today we serve over 500 million patients every year with our pharmaceutical products and innovative healthcare solutions. In everything we do we are led by three questions: are we making high-quality pharmaceuticals better affordable, better globally available, or better than before?

For information about our product portfolio and innovative healthcare solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963

TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. Our purpose is to improve
patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.


Featured Video Play Icon

TIEFENBACHER GROUP AT DCAT 2022 – THANKS FOR MEETING US IN NEW YORK CITY!

One of the world´s most important pharma events – DCAT week in New York City – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER GROUP presenting our latest product portfolio and innovations to our existing and potential new partners. Check out our short video to get some impressions!

For further information about our product portfolio and innovative health care solutions please contact TIEFENBACHER GROUP: info@aet.eu or visit us on: www.tiefenbachergroup.com

About TIEFENBACHER GROUP – Pioneering Healthcare since 1963
TIEFENBACHER GROUP is a purpose-driven and 100% family-owned healthcare company providing solutions along the entire pharmaceutical value chain. Our purpose is to improve patients´ lives by creating pharmaceuticals more affordable, more available, and better than before.